View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 17, 2011

OncoVista Begins Additional Safety Study of Cancer Drug

OncoVista Innovative Therapies has initiated an additional safety study of cancer drug OVI-117 in a second animal species. OVI-117 is used for the treatment of solid tumours, such as breast, colon and prostate cancers, and targets thymidylate synthase. OncoVista Innovative Th

By cms admin

OncoVista Innovative Therapies has initiated an additional safety study of cancer drug OVI-117 in a second animal species.

OVI-117 is used for the treatment of solid tumours, such as breast, colon and prostate cancers, and targets thymidylate synthase.

OncoVista Innovative Therapies CEO Alexander Weis said that the additional safety study of OVI-117 is an important step in efforts to bring the drug candidate into clinical trials.

The company is completing the GLP animal toxicology studies and preparing the IND submission to the US Food and Drug Administration, and expects to launch a Phase I trial in the fourth quarter of 2011.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology